Stock Evaluator: Aprea Therapeutics, Inc. (APRE)

Aprea Therapeutics, Inc. APRE

$0.41 -0.01 -2.38%
November 16, 2026 4:00:00 PM EST November 10, 2021 Volume: 140,453
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD NASD | DELAYED PRICE
SECTOR INDUSTRY
Health Care Biotechnology

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications. The company is headquartered in Doylestown, Pennsylvania.

Commentary & Analysis


Financial Summary

Share Statistics APRE Industry
Median
Percentile
(All Stocks)
Market Cap (Mil) $5.9 $211.8 5%
Shares Out (Mil) 53.7 55.4 49%
Institutional Ownership 56.1% 93.0% 38%
Float (Mil) 7.9 41.5 17%
Beta 1.69 0.99 86%
Avg Daily Volume (000s) 94 553 35%
Price Change
(52-week)
(67.0%) 42.8% 13%
Growth APRE Industry
Median
Percentile
(All Stocks)
Sales (5yr) na 13.2% na
Net Income (5yr) 25.1% (10.3%) 80%
EPS (5yr) 48.0% 15.8% 92
Dividends (5yr) na 0.0% 0%
Cash Flow (5yr) 49.6% (15.7%) 93%
Estimates Qtrly Current
Fiscal
Year
Next
Fiscal
Year
# of Estimates 3 3 3
Current EPS ($0.100) ($0.390) ($0.437)
Month Ago EPS ($0.090) ($0.335) ($0.340)
# Rev Up 0 0 1
# Rev Down 0 0 0
Three Months Ago EPS ($0.077) ($0.313) ($0.290)
Year/Year Chg 11.1% (79.8%) (72.0%)
Financials APRE Industry
Median
Percentile
(All Stocks)
Sales (TTM) (Mil) na $41 na
Net Income (TTM) (Mil) ($14) ($44) 26%
EPS (TTM) ($0.435) ($1.500) 28%
Operating Cash Flow (TTM) (Mil) ($13) ($35) 18%
Net Cash Flow (TTM) (Mil) na $-0 na
Long-Term Debt (Q1) (Mil) $0 $4 0%
Enterprise Value (Q1) (Mil) ($31) $147 1%
Valuation APRE Industry
Median
Percentile
(All Stocks)
P/B 0.17 2.01 3%
P/E na 17.9 na
Dividend Yield na 0.0% na
PEG (5yr hist) na 1.0 na
Ratios APRE Industry
Median
Percentile
(All Stocks)
Gross Margin na 67.9% na
Net Margin na (50.6%) na
ROA (53.2%) (47.4%) 11%
ROE (62.8%) (53.1%) 13%
Liabilities to Assets 10.2% 29.7% 6%
F-Score 3 3 18%

Aprea Therapeutics, Inc. did not pass any screens on 11/13/2026.

Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.

Ⓒ 2026 American Association of Individual Investors